Transvaginal Mesh Lawsuit Update: Rottenstein Law Group Responds to Court Order to Remove American Medical Systems as Mesh Defendant

Share Article

American Medical Systems and other subsidiaries of Endo Pharmaceuticals, Inc. were removed earlier this month as defendants in the federal consolidations of transvaginal mesh lawsuits (MDL-2325, U.S. District Court for the Southern District of West Virginia), according to documents reviewed by the vaginal mesh lawyers at the Rottenstein Law Group.

Transvaginal mesh lawsuits

Transvaginal mesh lawsuits

The removal of those defendants from the multidistrict litigation does not mean that American Medical Systems cannot be sued for the serious alleged side effects of its transvaginal mesh products.

American Medical Systems and other subsidiaries of Endo Pharmaceuticals, Inc. were removed earlier this month as defendants in the federal consolidations of transvaginal mesh lawsuits (MDL-2325, U.S. District Court for the Southern District of West Virginia), according to court documents reviewed by the Rottenstein Law Group, a transvaginal mesh law firm.

A court order* from Chief Judge Joseph R. Goodwin said that “the court will dismiss in all pending cases (whether filed directly or transferred), all claims pending against the Endo entities without prejudice.”

“The removal of those defendants from the multidistrict litigation does not mean that American Medical Systems cannot be sued for the serious alleged side effects of its transvaginal mesh products,” said Rochelle Rottenstein, principal of the Rottenstein Law Group. “What it means is that they won’t be included in the existing MDLs, which is a pretrial consolidation of common causes and acts of discovery.”

The court order applies to all of the federal transvaginal mesh lawsuits filed in the U.S. District Court for the Southern District of West Virginia, including those in In re: Boston Scientific, Pelvic Repair Systems Products Liability Litigation (MDL-2326); In re: C.R. Bard, Pelvic Repair Systems Products Liability Litigation (MDL-2187); and In re: Ethicon, Pelvic Repair Systems Products Liability Litigation (MDL-2327), according to court documents.

Since 2011, the U.S. Food and Drug Administration has received reports of problems associated with transvaginal mesh used to treat pelvic organ prolapse and stress urinary incontinence. Serious complications associated with the use of transvaginal mesh are not rare, according to the FDA.** Some serious side effects include bleeding, urinary problems, pain and infection.

In February 2013 the nation’s first trial involving Ethicon’s transvaginal mesh resulted in a jury award of more than $11 million in compensatory and punitive damages to plaintiff Linda Gross.*** There are more than 4,000 trials pending across the country, according to Bloomberg, including more than 2,000 in New Jersey.

The Rottenstein Law Group maintains a comprehensive website with a wealth of information regarding transvaginal mesh lawsuits and side effects. Women who believe they are suffering from serious side effects related to their transvaginal mesh surgery should contact Rottenstein Law Group today for a free consultation.

*http://www.wvsd.uscourts.gov/MDL/amsinc/pdfs/PTO_56.pdf

**http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/UroGynSurgicalMesh/default.htm

***bloomberg.com/news/2013-02-28/j-j-owes-7-76-million-in-punitives-in-vaginal-mesh-case.html

About THE ROTTENSTEIN LAW GROUP
The Rottenstein Law Group is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and drugs. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group, LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
http://www.rotlaw.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rochelle Rottenstein, Esq.
Follow us on
Visit website